...
首页> 外文期刊>Neurosurgery >Proton beam stereotactic radiosurgery for pediatric cerebral arteriovenous malformations
【24h】

Proton beam stereotactic radiosurgery for pediatric cerebral arteriovenous malformations

机译:质子束立体定向放射外科治疗小儿脑动静脉畸形

获取原文
获取原文并翻译 | 示例

摘要

Background: For cerebral arteriovenous malformations (AVMs) determined to be high risk for surgery or endovascular embolization, stereotactic radiosurgery (SRS) is considered the mainstay of treatment. Objective: To determine the outcomes of pediatric patients with AVMs treated with proton SRS. Methods: We reviewed the records of 44 consecutively treated pediatric patients (younger than 18 years of age) who underwent proton SRS at our institution from 1998 to 2010. The median target volume was 4.5 ± 5.9 mL (range, 0.3-29.0 mL) and the median maximal diameter was 3.6 ± 1.5 cm (range, 1-6 cm). Radiation was administered with a median prescription dose of 15.50 ± 1.87 CGE to the 90% isodose. Results: At a median follow-up of 52 ± 25 months, 2 patients (4.5%) had no response, 24 patients (59.1%) had a partial response, and 18 patients (40.9%) experienced obliteration of their AVM. The median time to obliteration was 49 ± 26 months, including 17 patients who underwent repeat proton radiosurgery. Four patients (9%) experienced hemorrhage after treatment at a median time of 45 ± 15 months. Univariate analysis identified modified AVM scale score (P =.045), single fraction treatment (0.04), larger prescription dose (0.01), larger maximum dose (<0.001), and larger minimum dose (0.01) to be associated with AVM obliteration. Conclusion: High-risk AVMs can be safely treated with proton radiosurgery in the pediatric population. Because protons deposit energy more selectively than photons, there is the potential benefit of protons to lower the probability of damage to healthy tissue in the developing brain.
机译:背景:对于确定为手术或血管内栓塞高风险的脑动静脉畸形(AVM),立体定向放射外科(SRS)被认为是治疗的主要手段。目的:确定接受质子SRS治疗的小儿AVM患者的结局。方法:我们回顾了1998年至2010年间在本机构接受质子SRS治疗的44例连续接受治疗的小儿患者(18岁以下)的记录。中位目标量为4.5±5.9 mL(范围0.3-29.0 mL),且中值最大直径为3.6±1.5厘米(范围1-6厘米)。 90%的等剂量剂量的中位处方剂量为15.50±1.87 CGE。结果:在52±25个月的中位随访中,2例患者(4.5%)无反应,24例患者(59.1%)部分缓解,18例患者(40.9%)的AVM消失。中位闭塞时间为49±26个月,包括17例行重复质子放射外科手术的患者。四名患者(9%)在治疗后的中位时间为45±15个月时发生出血。单因素分析确定与AVM闭塞相关的改良AVM量表评分(P = .045),单次治疗(0.04),较大处方剂量(0.01),较大最大剂量(<0.001)和较大最小剂量(0.01)。结论:小儿人群质子放射外科可以安全治疗高危型AVM。由于质子比光子更有选择性地沉积能量,因此质子具有降低对发育中的大脑健康组织造成损害的可能性的潜在好处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号